Safety and immunogenicity of an adjuvanted recombinant spike protein-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, SpikeVet™, in selected Carnivora, Primates and Artiodactyla in Australian zoos.

Publication date: Feb 12, 2024

Concepts Keywords
4weeks immunogenicity
Australian safety
Coronavirus SARS-CoV-2
Pharmacol SpikeVet™
Zoos vaccine
zoo animals


Type Source Name
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO vaccine
disease VO vaccinated
disease VO immunized
disease VO vaccination
disease MESH infection
disease VO effective

Original Article

(Visited 1 times, 1 visits today)